Key Market Indicator:
F&G: 40
25.289,84 NASDAQ · 48.612,00 DOW · 6.895,60 S&P · 4.295,56 Gold · 60,71 BRENT

One Community. One Spirit. N#1 Broker.
all asset classes · all possibilities

Switch View
Hedge the Peak | Protect your Profits
US9286611077
Filter zurücksetzen
© PR Newswire
11.12.2025
ISIN: US9286611077
VolitionRX Ltd
VNRX
LISTED
XASE
Volition Solves Liquid Biopsy's "Needle in a Haystack" Problem; Achieves 180-fold (18,000%) Enrichment
Article
News Preview
HENDERSON, Nev., Dec. 11, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, announces preprint availability of a new manuscript entitled "Direct analysis of transcription factor protected cfDNA in plasma by ChIP-seq: Measurement of altered CTCF binding in cancer is a novel biomarker f...
Themefolio
Profiler
Peergroup
© PR Newswire
08.12.2025
ISIN: US9286611077
VolitionRX Ltd
VNRX
LISTED
XASE
Volition Announces Two Abstracts were Presented at the North America Conference on Lung Cancer
Article
News Preview
HENDERSON, Nev.,, December 8, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, announces the presentation of two abstracts at the North America Conference on Lung Cancer (NACLC) in Chicago recently. The posters highlighted the use of its Nu.Q® Cancer assays in the management of lung...
Themefolio
Profiler
Peergroup
© PR Newswire
04.12.2025
ISIN: US9286611077
VolitionRX Ltd
VNRX
LISTED
XASE
VolitionRx Limited Announces Inclusion of its Nu.Q® NETs Assay as Innovative Biomarker in France's Real-World Evaluation of Early Detection of Sepsis
Article
News Preview
HENDERSON, Nev., Dec. 4, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announces the inclusion of its Nu.Q® NETs H3.1 assay in "DETECSEPS", a real-world evaluation of early detection of sepsis. DETECSEPS Consortium was awarded winner of the "Challenge Prevention" call for pr...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
More Info
Knowing what matters
Short sale statistics, hedge fund activities and much more user-friendly information
© PR Newswire
25.11.2025
ISIN: US9286611077
VolitionRX Ltd
VNRX
LISTED
XASE
VolitionRx Limited Announces the First Sale of the Nu.Q® Cancer Assays for Clinical Certification in Preparation for Routine Clinical Use
Article
News Preview
HENDERSON, Nev., Nov. 25, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announces the first sale of its Nu.Q® Cancer assays to one of Europe's leading cancer centers, the Hospices Civils de Lyon, in Lyon, France. Professor Léa Payen, Professor in Toxicology and Biochemistry,...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© PR Newswire
13.11.2025
ISIN: US9286611077
VolitionRX Ltd
VNRX
LISTED
XASE
VolitionRx Limited Announces Third Quarter 2025 Financial Results and Business Update
Article
News Preview
Conference call to discuss financial and operational results scheduled for Friday, November 14 at 8:30 a.m. U.S. Eastern Time HENDERSON, Nevada, Nov. 13, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-natio...
Themefolio
Profiler
Peergroup
© PR Newswire
10.11.2025
ISIN: US9286611077
VolitionRX Ltd
VNRX
LISTED
XASE
VolitionRx Limited Schedules Third Quarter 2025 Earnings Conference Call and Business Update
Article
News Preview
Conference call to take place on Friday, November 14 at 8:30 a.m. U.S. Eastern Time HENDERSON, Nev., Nov. 10, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announces that it will host a conference call on Friday, November 14 at...
Themefolio
Profiler
Peergroup
© PR Newswire
17.10.2025
ISIN: US9286611077
VolitionRX Ltd
VNRX
LISTED
XASE
Volition Donates Nu.Q® Vet Cancer Tests to HOPE Animal-Assisted Crisis Response Dogs
Article
News Preview
HENDERSON, Nev., Oct. 17, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), and its subsidiary, Volition Veterinary Diagnostics Development LLC, in line with their corporate social responsibility strategy announces participation at the HOPE Animal-Assisted Crisis Response Dogs (HOPE AACR...
Themefolio
Profiler
Peergroup
© PR Newswire
10.10.2025
ISIN: US9286611077
VolitionRX Ltd
VNRX
LISTED
XASE
VolitionRx Limited Announces Pricing of $6.0 Million Underwritten Public Offering of Common Stock and Common Stock Warrants
Article
News Preview
HENDERSON, Nev., Oct. 10, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition" or the "Company"), a multi-national epigenetics company, announced today the pricing of an underwritten public offering of 11,550,000 shares of its common stock and warrants to purchase up to 11,550,000 shares of i...
Themefolio
Profiler
Peergroup
© PR Newswire
09.10.2025
ISIN: US9286611077
VolitionRX Ltd
VNRX
LISTED
XASE
VolitionRx Limited Announces Proposed Underwritten Public Offering of Common Stock and Common Stock Warrants
Article
News Preview
HENDERSON, Nev., Oct. 9, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition" or the "Company"), a multi-national epigenetics company, announced today that it is proposing to offer and sell, in an underwritten public offering, shares of its common stock and accompanying common stock purchase...
Themefolio
Profiler
Peergroup
© PR Newswire
02.10.2025
ISIN: US9286611077
VolitionRX Ltd
VNRX
LISTED
XASE
Volition Sponsors Upcoming GenomeWeb Webinar
Article
News Preview
HENDERSON, Nev., Oct. 2, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announces the sponsorship of a GenomeWeb webinar entitled "Beyond the Genome: Measuring Epigenetic Modifications Across Matrices for Biomarker and Drug Discovery" on Wed...
Themefolio
Profiler
Peergroup
© PR Newswire
31.03.2025
ISIN: US9286611077
VolitionRX Ltd
VNRX
LISTED
XASE
VolitionRx Limited Announces Full Fiscal Year 2024 Financial Results and Business Update
News Preview
Conference call to discuss financial and operational results scheduled for Monday, March 31 at 4:30 p.m. U.S. Eastern Time HENDERSON, Nevada, March 31, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announces financial results and a business update for the fourth quarter and...
Themefolio
Profiler
Peergroup
© PR Newswire
28.03.2025
ISIN: US9286611077
VolitionRX Ltd
VNRX
LISTED
XASE
Volition Announces Two Poster Presentations at ESMO's European Lung Cancer Congress 2025
News Preview
Studies demonstrate how Volition's Nu.Q®H3K27Me3 biomarker, when combined with ctDNA, may improve the prognostic value for overall survival and could help inform treatment decisions in NSCLC; and how Volition's Nu.Q® H3.1, low-cost immunoassay may be utilized  for the early identification of subjects at high risk of cancer HENDERSON, Nev., March...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© PR Newswire
27.03.2025
ISIN: US9286611077
VolitionRX Ltd
VNRX
LISTED
XASE
Volition to Host Virtual Investor Event on Nu.Q® Cancer, "A Look to the Future of Cancer Diagnostics", on April 9, 2025
News Preview
HENDERSON, Nev., March 27, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announces it will host a virtual investor event on Wednesday, April 9, 2025, at 10:00 AM ET, featuring Volition's Gael Forterre, Chief Commercial Officer, Dr. Andrew Retter, Chief Medical Officer and D...
Themefolio
Profiler
Peergroup
© PR Newswire
26.03.2025
ISIN: US9286611077
VolitionRX Ltd
VNRX
LISTED
XASE
VolitionRx Announces Pricing of up to $2.3 Million Registered Direct Offering
Article
News Preview
Up to $2.3 million up front with up to an additional $1.1 million of potential aggregate gross proceeds upon the exercise in full of common stock purchase warrants HENDERSON, Nev., March 26, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition" or the "Company"), a multi-national epigenetics company, announces today that it ha...
Themefolio
Profiler
Peergroup
© PR Newswire
25.03.2025
ISIN: US9286611077
VolitionRX Ltd
VNRX
LISTED
XASE
VolitionRx Limited Schedules Full Fiscal Year 2024 Earnings Conference Call and Business Update
News Preview
Conference call to take place on Monday, March 31 at 4:30 p.m. U.S Eastern Time HENDERSON, Nev., March 25, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announces that it will host a conference call on Monday, March 31 at 4.30 p.m. U.S. Eastern Time to discuss its financial and operating results for the fourth q...
Themefolio
Profiler
Peergroup
© PR Newswire
21.03.2025
ISIN: US9286611077
VolitionRX Ltd
VNRX
LISTED
XASE
Volition's Nu.Q® Cancer Diagnostics Test Aims To Disrupt the Multi-Billion Dollar Liquid Biopsy Industry
Article
News Preview
Volition study shows rapid, low-cost, automated Nu.Q® Cancer test accurately detects human cancers at high specificity HENDERSON, Nev., March 21, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ('Volition'), a multi-national epigenetics company, today announces the results of a study which shows that an automated Nu.Q® Cancer immuno...
Themefolio
Profiler
Peergroup
© PR Newswire
20.03.2025
ISIN: US9286611077
VolitionRX Ltd
VNRX
LISTED
XASE
Volition Introduces Nu.Q® Cancer Blood Test in New Industry Primer for Lung Cancer
News Preview
 "Lung Cancer: Hope of a Brighter Tomorrow" illustrates how Nu.Q® Cancer Test aims to transform the diagnosis, treatment and monitoring in the $4 billion lung cancer market1 HENDERSON, Nev., March 20, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announces the release of Vo...
Themefolio
Profiler
Peergroup
© PR Newswire
17.03.2025
ISIN: US9286611077
VolitionRX Ltd
VNRX
LISTED
XASE
Volition Proudly Sponsors the 44th ISICEM Congress
Article
News Preview
Volition to host multiple presentations at the International Symposium on Intensive Care & Emergency Medicine in Brussels, Belgium, from March 18 - 21  HENDERSON, Nev., March 17, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, announced its participation at the 44th Annual ISIC...
Themefolio
Profiler
Peergroup
© PR Newswire
13.03.2025
ISIN: US9286611077
VolitionRX Ltd
VNRX
LISTED
XASE
Volition Signs first ever Nu.Q® Vet Cancer Test Automation Agreement with Fujifilm Vet Systems
Article
News Preview
HENDERSON, Nev., March 13, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announced the expansion of its Nu.Q® Vet Cancer Test supply agreement (the "Agreement") with Fujifilm Vet Systems Co. Ltd ("Fujifilm Vet Systems") in Japan, to include Volition's chemiluminescent immun...
Themefolio
Profiler
Peergroup
© PR Newswire
11.03.2025
ISIN: US9286611077
VolitionRX Ltd
VNRX
LISTED
XASE
Volition Announces First Patient Enrolled in NTU Hospital's Prospective Validation Study of Nu.Q® Lung Cancer Test
News Preview
Published study shows Nu.Q® Lung Cancer Test differentiated malignant and benign nodules found by Low Dose CT screening. The study is expected to be completed by the end of 2025 HENDERSON, Nev., March 11, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, announces first patient enrol...
Themefolio
Profiler
Peergroup
© PR Newswire
04.03.2025
ISIN: US9286611077
VolitionRX Ltd
VNRX
LISTED
XASE
Volition's Nu.Q® Discover Biomarkers to be utilized in Human Clinical Study Sponsored by Leading Pharmaceutical Company for the First Time
News Preview
Nu.Q® Discover tools provide drug developers and scientists with a range of rapid epigenetic profiling assays across pre-clinical and clinical development pathways from discovery to market ready HENDERSON, Nev., March 4, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announc...
Themefolio
Profiler
Peergroup
© PR Newswire
28.02.2025
ISIN: US9286611077
VolitionRX Ltd
VNRX
LISTED
XASE
Volition Showcases Nu.Q® Vet Cancer Test at the 97th WVC Annual Conference
News Preview
Volition will showcase presentations from Dr. Sue Ettinger, aka Dr. Sue Cancer Vet, Dr. Brett Cordes, DVM, and Dr. Tom Butera, DVM Representatives will also be available at exhibition booth #2943 HENDERSON, Nev., Feb. 28, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, Volition is...
Themefolio
Profiler
Peergroup
© PR Newswire
06.02.2025
ISIN: US9286611077
VolitionRX Ltd
VNRX
LISTED
XASE
Volition Signs First Commercial Project Utilizing Rapid High-Throughput Model in the Study of NETosis
Article
News Preview
Expanding commercial offering as a bio-partnering model, currently in active discussions with pharmaceutical companies  HENDERSON, Nev., Feb. 6, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) Volition a multi-national epigenetics company, announces its first commercial sale of Volition's High Throughput Synthetic Sepsis method tha...
Themefolio
Profiler
Peergroup
© PR Newswire
05.02.2025
ISIN: US9286611077
VolitionRX Ltd
VNRX
LISTED
XASE
Volition to Host Virtual Investor Event on Nu.Q® NETs, "Casting a New Light on Sepsis Management", on February 14, 2025
Article
News Preview
HENDERSON, Nev., Feb. 5, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announced it will host a virtual investor event on Friday, February 14, 2025 at 8:00 AM ET, featuring Volition company management Dr. Andrew Retter, Chief Medical Officer and Gael Forterre, Chief Commerc...
Themefolio
Profiler
Peergroup
© PR Newswire
30.01.2025
ISIN: US9286611077
VolitionRX Ltd
VNRX
LISTED
XASE
Large clinical study establishes Nu.Q® NETs H3.1 as an independent predictor of 28-day mortality in sepsis
Article
News Preview
HENDERSON, Nev., Jan. 30, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announced the results of a large-scale study which shows that its Nu.Q®NETs H3.1 biomarker is an independent predictor of 28-day mortality and need for renal replacement therapy (RRT) in sepsis and sept...
Themefolio
Profiler
Peergroup
© PR Newswire
08.01.2025
ISIN: US9286611077
VolitionRX Ltd
VNRX
LISTED
XASE
Volition Issues Business Review 2024
Article
News Preview
HENDERSON, Nev., Jan. 8, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition" or the "Company"), a multi-national epigenetics company, has issued a Business Review of 2024, outlining its key highlights from the past year. Volition's major achievements in 2024 include: Expanded access to the Nu.Q® Vet Cancer Test – now availa...
Themefolio
Profiler
Peergroup
© PR Newswire
12.12.2024
ISIN: US9286611077
VolitionRX Ltd
VNRX
LISTED
XASE
VolitionRx Appoints LifeSci Advisors as Investor Relations Consultants
Article
News Preview
Volition to participate in the upcoming 14th Annual LifeSci Partners Corporate Access Event on January 15th, 2025 at the Beacon Grand Hotel in San Francisco. HENDERSON, Nev., Dec. 12, 2024 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition" or the "Company"), a multi-national epigenetics company, announced that it has retained Li...
Themefolio
Profiler
Peergroup
© PR Newswire
10.12.2024
ISIN: US9286611077
VolitionRX Ltd
VNRX
LISTED
XASE
Study shows Nu.Q® Lung Cancer Test differentiated malignant and benign nodules found by Low Dose CT screening
Article
News Preview
HENDERSON, Nev., Dec. 10, 2024 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announced the results of a large-scale study which shows that its Nu.Q® Cancer Test differentiated between malignant and benign pulmonary nodules, found by Low Dose CT (LDCT) scan, in patients suspected...
Themefolio
Profiler
Peergroup
© PR Newswire
14.11.2024
ISIN: US9286611077
VolitionRX Ltd
VNRX
LISTED
XASE
VolitionRx Limited Announces Third Quarter 2024 Financial Results and Business Update
Article
News Preview
Conference call to discuss financial and operational results scheduled for Friday, November 15 at 8:30 a.m. U.S. Eastern Time HENDERSON, Nev.  , Nov. 14, 2024 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announces financial results and a business update for the third quarter of...
Themefolio
Profiler
Peergroup
© PR Newswire
08.11.2024
ISIN: US9286611077
VolitionRX Ltd
VNRX
LISTED
XASE
VolitionRx Limited Schedules Third Quarter 2024 Earnings Conference Call and Business Update
Article
News Preview
Conference call to take place on Friday, November 15 at 8:30 a.m. U.S Eastern Time HENDERSON, Nev., Nov. 8, 2024 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announces that it will host a conference call on Friday, November 15 at 8.30 a.m. U.S. Eastern Time to discuss its financial and operating results for the thir...
Themefolio
Profiler
Peergroup
© PR Newswire
06.11.2024
ISIN: US9286611077
VolitionRX Ltd
VNRX
LISTED
XASE
Volition Appoints Timothy I. Still as Chairman
Article
News Preview
HENDERSON, Nev., Nov. 6, 2024 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, has appointed Timothy Still as Chairman of its board of directors, effective November 06, 2024....
Themefolio
Profiler
Peergroup
© PR Newswire
31.10.2024
ISIN: US9286611077
VolitionRX Ltd
VNRX
LISTED
XASE
Multiple studies show Nu.Q® NETs test could predict sepsis patients at risk of deteriorating
Article
News Preview
HENDERSON, Nev., Oct. 31, 2024 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, has published a report, from its 'NETs in sepsis management' symposium at ESICM Lives 2024 last month, which concluded that Nu.Q® NETs could be used to predict patients at greater risk of deteriorating from s...
Themefolio
Profiler
Peergroup
© PR Newswire
09.10.2024
ISIN: US9286611077
VolitionRX Ltd
VNRX
LISTED
XASE
Volition to share new 'NETs in sepsis management' data insights at upcoming webinar
Article
News Preview
HENDERSON, Nev., Oct. 9, 2024 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, is taking part in a webinar hosted by Edison Group, to expound new data, presented at ESICM LIVES 2024, the annual congress of the European Society of Intensive Care Medicine, earlier this week.       Given th...
Themefolio
Profiler
Peergroup
© PR Newswire
03.10.2024
ISIN: US9286611077
VolitionRX Ltd
VNRX
LISTED
XASE
Volition hosts NETs in sepsis management symposium at ESICM Lives 2024
Article
News Preview
HENDERSON, Nev., Oct. 3, 2024 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, is hosting a symposium at ESICM Lives 2024 in Barcelona on October 7, 2024, during which experts from across the globe will present findings from large, independent studies regarding the potential of using Nu....
Themefolio
Profiler
Peergroup
© PR Newswire
30.09.2024
ISIN: US9286611077
VolitionRX Ltd
VNRX
LISTED
XASE
Volition Appoints Dr. Ethel Rubin as an Independent Director
Article
News Preview
HENDERSON, Nev., Sept. 30, 2024 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, has appointed Dr. Ethel Rubin to its board of directors, as an independent director, effective September 30, 2024. Dr. Rubin has also been appointed as a member of the Audit Committee and the Compensation Co...
Themefolio
Profiler
Peergroup
© PR Newswire
11.09.2024
ISIN: US9286611077
VolitionRX Ltd
VNRX
LISTED
XASE
Volition Hosts KOL Roundtable on Sepsis
Article
News Preview
HENDERSON, Nev., Sept. 11, 2024 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, hosted a Key Opinion Leader ("KOL") roundtable in Paris this weekend and brought together some of the world's leading experts in sepsis to explore the potential of using Volition's Nu.Q® NETs technology effe...
Themefolio
Profiler
Peergroup
© PR Newswire
14.08.2024
ISIN: US9286611077
VolitionRX Ltd
VNRX
LISTED
XASE
VolitionRx Limited Announces Second Quarter 2024 Financial Results and Business Update
Article
News Preview
Conference call to discuss financial and operational results scheduled for Thursday, August 15 at 8:30 a.m. U.S. Eastern Time HENDERSON, Nev., Aug. 14, 2024 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announced financial results and a business update for the second quarter of...
Themefolio
Profiler
Peergroup
© PR Newswire
09.08.2024
ISIN: US9286611077
VolitionRX Ltd
VNRX
LISTED
XASE
VolitionRx Announces Pricing of up to $21.5 Million Registered Direct Offering
Article
News Preview
$7 million upfront with up to an additional $14.5 million of potential aggregate gross proceeds upon the exercise in full of milestone-linked warrants HENDERSON, Nev., Aug. 9, 2024 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition" or the "Company"), a multi-national epigenetics company, announced today that it has entered into...
Themefolio
Profiler
Peergroup
© PR Newswire
09.07.2024
ISIN: US9286611077
VolitionRX Ltd
VNRX
LISTED
XASE
Volition appoints PharmaVentures for Capture PCR™ and oncology portfolio licensing
Article
News Preview
HENDERSON, Nev., July 9, 2024 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, has appointed PharmaVentures Ltd ("PharmaVentures"), a leading transaction advisory firm, to provide strategic advice and transactional support on the out-license of Volition's expanding oncology portfolio. P...
Themefolio
Profiler
Peergroup
© PR Newswire
27.06.2024
ISIN: US9286611077
VolitionRX Ltd
VNRX
LISTED
XASE
VolitionRx Limited Issues Mid-Year Review Ahead of 2024 Annual Meeting
Article
News Preview
HENDERSON, Nev., June 27, 2024 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, has issued a mid-year review to stockholders, ahead of its Annual Meeting of Stockholders to be held on July 2, 2024. Volition's mid-year review encompasses key highlights including: Expanding access to the ...
Themefolio
Profiler
Peergroup
© PR Newswire
29.05.2024
ISIN: US9286611077
VolitionRX Ltd
VNRX
LISTED
XASE
VolitionRx Limited to Present at Jefferies Global Healthcare Conference
Article
News Preview
HENDERSON, Nevada, May 29, 2024 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, announced today that Cameron Reynolds, President and Group Chief Executive Officer, will present and be available for one-to-one meetings at the Jefferies Global Healthcare Conference in New York City. Pres...
Themefolio
Profiler
Peergroup
© PR Newswire
13.05.2024
ISIN: US9286611077
VolitionRX Ltd
VNRX
LISTED
XASE
VolitionRx Limited Announces First Quarter 2024 Financial Results and Business Update
Article
News Preview
Conference call to discuss financial and operational results scheduled for Tuesday, May 14 at 8:30 a.m. U.S. Eastern Time HENDERSON, Nev., May 13, 2024 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announced financial results and a business update for the first quarter of 2024. ...
Themefolio
Profiler
Peergroup
© PR Newswire
08.05.2024
ISIN: US9286611077
VolitionRX Ltd
VNRX
LISTED
XASE
VolitionRx Limited Schedules First Quarter 2024 Earnings Conference Call and Business Update
Article
News Preview
Conference call to take place on Tuesday May 14 at 8:30 a.m. U.S Eastern Time HENDERSON, Nev., May 8, 2024 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced it will host a conference call on Tuesday, May 14 at 8.30 a.m. U.S. Eastern Time to discuss its financial and operating results for the first quarter 2024,...
Themefolio
Profiler
Peergroup
© PR Newswire
23.04.2024
ISIN: US9286611077
VolitionRX Ltd
VNRX
LISTED
XASE
Nu.Q® Vet Cancer Test launched in-clinic in U.S. and Europe through Antech
Article
News Preview
HENDERSON, Nev., April 23, 2024 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, has announced that its Nu.Q® Vet Cancer Test is now available in-clinic to veterinarians across the U.S and Europe through Antech, a leading veterinary diagnostics company. Antech's in-clinic version of the...
Themefolio
Profiler
Peergroup
© PR Newswire
25.03.2024
ISIN: US9286611077
VolitionRX Ltd
VNRX
LISTED
XASE
VolitionRx Limited Announces Full Fiscal Year 2023 Financial Results and Business Update
Article
News Preview
Conference call to discuss financial and operational results scheduled for Tuesday, March 26 at 8:30 a.m. U.S. Eastern Time HENDERSON, Nev., March 25, 2024 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announced financial results and a business update for the full fiscal year en...
Themefolio
Profiler
Peergroup
© PR Newswire
21.03.2024
ISIN: US9286611077
VolitionRX Ltd
VNRX
LISTED
XASE
VolitionRx Limited Schedules Fourth Quarter and Full Year 2023 Earnings Conference Call and Business Update
Article
News Preview
Conference call to take place on Tuesday March 26 at 8:30 a.m. U.S Eastern Time HENDERSON, Nev. , March 21, 2024 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced it will host a conference call on Tuesday, March 26 at 8.30 a.m. U.S. Eastern Time to discuss its financial and operating results for the fourth quar...
Themefolio
Profiler
Peergroup
© PR Newswire
20.03.2024
ISIN: US9286611077
VolitionRX Ltd
VNRX
LISTED
XASE
Volition and Fujifilm Vet Systems Launch Nu.Q® Vet Cancer Test in Japan
Article
News Preview
HENDERSON, Nev. , March 20, 2024 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, has agreed a supply agreement with Fujifilm Vet Systems Co. Ltd ("Fujifilm Vet Systems"), a leading veterinary diagnostic laboratory service, to launch the Nu.Q® Vet Cancer Test to veterinarians in Japan....
Themefolio
Profiler
Peergroup
© PR Newswire
19.03.2024
ISIN: US9286611077
VolitionRX Ltd
VNRX
LISTED
XASE
Volition appoints Dr Andrew Retter as Chief Medical Officer
Article
News Preview
HENDERSON, Nev., March 19, 2024 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, has appointed Dr Andrew Retter as its Chief Medical Officer, effective April 1, 2024. Dr R...
Themefolio
Profiler
Peergroup
© PR Newswire
02.02.2024
ISIN: US9286611077
VolitionRX Ltd
VNRX
LISTED
XASE
Volition to Share Nu.Q® NETs Strategy Update at Upcoming Webinar
Article
News Preview
HENDERSON, Nev., Feb. 2, 2024 /PRNewswire/ -- VolitionRx Limited (NYSE American: VNRX) ("Volition"), a multi-national epigenetics company, is taking part in a webinar hosted by Edison Group, to update stakeholders on recent developments and ongoing studies for its Nu.Q® NETs test. The webinar takes place on Tuesday, February 13th at 10:30 AM U.S...
Themefolio
Profiler
Peergroup
© PR Newswire
04.01.2024
ISIN: US9286611077
VolitionRX Ltd
VNRX
LISTED
XASE
Volition Issues Business Review 2023
Article
News Preview
HENDERSON, Nev., Jan. 4, 2024 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, has issued a Business Review of 2023, outlining its key highlights from the past year. Volition's major achievements in 2023 include: Launching the Nu.Q® Vet Cancer Test in some significant markets through sev...
Themefolio
Profiler
Peergroup
© Newsfile
03.08.2022
ISIN: US9286611077
VolitionRX Ltd
VNRX
LISTED
XASE
VolitionRx Limited to Present at Investor Summit Group's Q3 Virtual Conference
Article
News Preview
Henderson, Nevada--(Newsfile Corp. - August 3, 2022) - VolitionRx Limited (NYSE American: VNRX) today announced that company executives Cameron Reynolds, CEO, and Scott Powell, Head of Investor Relations, will be attending the Q3 Virtual Investor Summit. During the presentation, VolitionRx Limited's Chief Executive Officer, Cameron Reynolds, will h...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
Indices
DAX, DOW, S&P, FTSE...
Realtime Trading
With & without leverage
Currencies
EUR, USD, JPY, BRL, GBP ....
50 FX-Pairs
Top Conditions, Tied spreads, Mini/Micro
Commodities
Brent, WTI, Coffee, Wheat....
Long & Short
Crude oil, Agricultural & more
Metals
Gold, Silver, Palladium, Platinum
Hedging
Soft-,Heavy-, Precious Metals
Stocks & ETF
TSLA, NFLX, NVDA, MSFT, AAPL ....
Leveraged Equity Trading
USA, Europe, Asia
More information, click here

More sector specific news

Your Press Release is missing or you want share news over GICS11? Drop us a line.

Gamechanger in online marketing · Innovation as a service · Upgrade your own internet presence.

XLB
XLE
XLU
XLY
XLF
XLP
XLV
XLK
XLC
XLI
XLRE
© 2025 Select Sector SPDRs
* * *
More Sector related Investment Ideas
XLB
XLE
XLU
XLY
XLF
XLP
XLV
XLK
XLC
XLI
XLRE
© 2025 WEBs Investments ETFs
About the newsfeed
#1
What types of information are provided on this portal - and what purpose does it serve?
The portal provides structured, stock market-relevant company information that is specifically assigned to a particular economic sector. The focus is on current announcements from official NewsWire sources, supplemented by company profiles, filter options by sector and sector-specific research aids. The aim is to offer an interested group of people a systematically structured research environment that improves their understanding of sector developments and corporate strategies.
#2
Why are companies categorized according to a certain system?
Financial markets consist of thousands of listed companies with very different business models. In order to create transparency and comparability, companies worldwide are assigned to standardized classifications. These classifications help investors to better analyze markets, identify sector-specific trends and make more targeted investment decisions.
#3
What classification standards exist for grouping companies?
There are various industry classifications that are used depending on the region or application. The best known include GICS (Global Industry Classification Standard), ICB (Industry Classification Benchmark), NAICS (North American Industry Classification System) and TRBC (Thomson Reuters Business Classification). Most institutional investors and ETFs worldwide use GICS or ICB as a benchmark.
#4
What classification standard is this financial information portal based on?
The portal uses the Global Industry Classification Standard (GICS), which was jointly developed by MSCI and S&P Dow Jones Indices. GICS is widely used in the institutional financial world and forms the basis for many global equity indices, ETFs and research systems.
#5
What exactly does GICS mean - and how is the system structured?
GICS stands for Global Industry Classification Standard. It is a hierarchical structure that divides listed companies worldwide into four levels: Sector, Industry Group, Industry Sector and Sub-Industry. In total, the system comprises 11 main sectors, over 60 industries and more than 150 sub-categories. It allows a consistent, internationally comparable analysis of economic activities.
#6
Why is GICS important in the financial world?
GICS offers a standardized language for investment decisions. It makes it possible to compare companies with similar business models - regardless of country, stock exchange or company size. Many investment funds, indices and research houses use GICS as a basis for portfolio construction, risk analysis or market screening. This means that it also makes sense for private investors to use this structure as a guide.
#7
Who decides which GICS sector a company is assigned to?
The allocation is made by the index providers MSCI and S&P Dow Jones on the basis of a company's main business segment. The decisive factor is the segment from which the company generates the majority of its sales or operating profit. Changes in the business model or strategic realignments can lead to a company being assigned to a different industry or even a different sector.
#8
What is meant by the GICS sector "Materials"?

The GICS "Materials" sector comprises companies that are active in the production, processing or refinement of raw materials. This includes industries such as chemicals, building materials, paper & forest products and the entire metallurgical and mining industry. The sector is highly cyclical and is particularly sensitive to economic fluctuations and changes in global demand.

#9
Which companies typically belong to the Materials sector?
Typical representatives are international groups from the areas of chemicals production (e.g. BASF), precious metal mining (e.g. Barrick Gold), building materials production (e.g. Heidelberg Materials) or industrial gases (e.g. Linde). The shares of these companies are often heavily dependent on commodity prices and play a central role in industrial value chains.
#10
Where does the company news on this page come from?
The news is based on verified and publicly available sources such as BusinessWire, GlobeNewswire, PR Newswire, EQS, Newsfile, ACCESSNewswire and other NewsWire services. These platforms are used by listed companies to publish mandatory ad hoc announcements, financial reports or strategic developments. All content is prepared in a structured manner and, if a corresponding categorization is possible, brought together in industry-specific clusters.
#11
How is the sector-specific mapping of messages carried out?
Categorization is based on structured metadata (e.g. ISIN, ticker, sector classification) and a combination of keyword analysis and GICS mapping. This ensures that all news is assigned to the correct sector and - if available - the correct sub-sector.
#12
Why is the materials sector particularly interesting for investors?
The Materials sector is closely linked to global industrial production and offers both cyclical growth opportunities and hedging opportunities against inflation and raw material shortages. In addition, many companies in this sector play a key role in future topics such as electromobility, the energy transition and sustainable building materials.
#13
What distinguishes this project from traditional financial information portals?
In contrast to generic portals, this project focuses exclusively and specifically on a particular sector. The advantage for interested investors: Sector-specific information, news, market movements and company profiles can be filtered and analyzed in a more targeted manner. This enables more in-depth research and greater relevance for thematic investment decisions.
#14
Are smaller companies also represented here or only large corporations?
The newsfeed takes into account both large caps and mid and small caps. As a clear mapping criterion is required in order to enable the most precise possible allocation to a cluster, the ISIN of the listed company is generally used for this purpose, provided that this can be made available or mapped via corresponding newsfeed parameters.
#15
How up-to-date are the displayed messages?
The content is updated regularly. The publication follows the publications of the information source, the NewsWire feeds of the underlying distributors. Incoming reports are automatically processed, classified and displayed on the page. Timestamps and source information ensure maximum transparency.
#16
Can I also filter the news by sub-sector?
Yes, this is a central feature of the site. Within a main sector, you can filter specifically for sub-sectors such as "Metals & Mining". For particularly popular industries or developments within a meta-sector, it is possible to deviate from standard clusters. Special categories with particular information value enable thematic analyses to be carried out even more precisely.
#17
Are there plans to process other metasectors in a similar way?
Yes, this financial information portal is part of an extensive project in which separate information portals are being created for all the main sectors. The aim is to provide investors with a systematic, sector-based research tool - regardless of index affiliation or provider perspective.
#18
Why do companies publish announcements via NewsWire services at all?
NewsWire services such as BusinessWire or PR Newswire fulfill a regulatory function: they enable companies to publish price-sensitive information publicly and without discrimination. In many countries, the use of such services is a prerequisite for fulfilling publication obligations under capital market law. They also enable companies to reach the media, analysts and investors in a targeted manner.
#19
Can private or inactive companies also appear in such notifications?
Generally not. The platform focuses exclusively on listed companies whose disclosures are based on regulatory requirements or corporate strategy measures. Although private or unlisted companies occasionally publish announcements, these are not systematically processed or classified here.
#20
What happens when a company changes its business model - does its sector classification also change?
Yes, as a rule - but not automatically. The responsible classification institutes (e.g. MSCI and S&P for GICS) regularly check the relevance and consistency of the classifications. If there is a significant change in a company's sales or profit profile, it may be reclassified to a different industry or even a different sector. This usually takes place after fixed review cycles or upon request.
#21
How is it ensured that a company is correctly categorized if it is active in several business areas?
The categorization is based on the dominant sales segment. If a company is active in several sectors but generates 70% of its turnover with chemical products, for example, it is assigned to the GICS sector "Materials" - even if it also has activities in the energy or transportation sector. In borderline cases, additional qualitative assessment criteria apply.
#22
Are there any legal risks in the further use of the displayed content?
The content comes from public sources, but is partially subject to copyright protection - particularly with regard to text structure and layout. The excerpts and links provided on this portal are made within the scope of permitted use (e.g. right to quote or editorial processing). However, commercial use by third parties is not permitted without the express permission of the original providers.
#23
Who can I contact if I have general questions or legal concerns?
A central contact point is available for general inquiries, information on company recordings, compliance issues or copyright-relevant aspects. In rare cases, for example in the case of erroneously published information or justified requests for deletion, a review and, if necessary, removal from the public feed can take place. Please only use the official contact option in the legal notice or at the bottom of the page.
#24
Is advertising or third-party content also displayed on the portal?
Yes, in defined areas the portal can display advertising content or product-specific information from third parties - for example on sector-related financial services, research offers or trading platforms. This content is clearly marked as advertising or partner information and is separate from the editorial or automatically processed company news.
#26
Can I give feedback on the platform or submit suggestions?
Absolutely - feedback is expressly welcome. The platform is an open information service that is continuously being developed. Comments on functionality, data quality, usability or thematic extensions help to optimize the service for the benefit of users. You can submit your suggestions informally via the contact page or special feedback forms.
#27
I am an information provider - can I cooperate with the portal?
Yes, the portal is open to content-related, technical or editorial cooperation, provided that this contributes to the quality, relevance or dissemination of the offering. If you offer content, interfaces or services that could be useful in the context of stock market-related information, we would be pleased to hear from you. The platform offers flexible integration options and a professional environment for quality-assured content.
#28
Can the platform technology also be used for other applications or partners?
Yes, the platform is based on a modular, scalable infrastructure that can be adapted to different information contexts and industry models. Technical components such as data aggregation, structuring logic, classification mechanisms and semantic filters can also be made available for external projects or individual applications on request. Please contact us for cooperation or license models.
#29
Can the underlying company data also be licensed or reused?
Structured access to selected master data of listed companies - such as GICS mapping, ISIN mapping, news feeds or metadata filters - is generally possible. The offer is aimed in particular at information service providers, research platforms or data-driven financial applications. Data can be provided via defined interfaces (e.g. API) or exportable formats, depending on the intended use and license framework.
#30
What forms of cooperation with external partners are conceivable?
Basically open. Possible forms of cooperation range from technical integrations and shared data models to content syndication or white label solutions. Partnerships with institutions that are looking for access to quality-assured data, dynamically structured news or sector-specific analyses - for example in the FinTech, media or research environment - are particularly interesting. We look forward to hearing from business development or product management departments.
#31
Why does this portal differ technically and conceptually from other information offerings?
Because no one from outside the industry is trying to understand the financial market here - but because the know-how comes from the heart of the financial world. The technical platform was developed by a team that combines in-depth market knowledge with innovative system design. The result: information architecture with real relevance, not shop window technology.
#32
What makes the technical solution particularly interesting for operators of their own financial portals?
In addition to high adaptability, the platform impresses with its modular structure and the consistent implementation of industry-specific logic - from GICS mapping to metadata filtering. For providers who operate their own information portals, sector-specific data structures, news feeds or visualizations can be quickly integrated on this basis - either as a white label, API module or embedded solution.
#33
Why can a collaboration go beyond traditional development services?
Because we don't just program, we think: The technological implementation is based on a deep understanding of market cycles, regulations, data formats and investor needs. Anyone who cooperates with this platform benefits from a sparring partner at eye level - both technically and professionally. This creates added value that goes far beyond pure IT expertise.
#34
Note on copyright and the processing of original content
The corporate news presented on this information portal is based on publicly accessible sources such as BusinessWire, GlobeNewswire, PR Newswire or comparable news services. The content is processed as part of an automated or editorially supported structuring process without changing, shortening or reinterpreting the content of the original information. This is so-called "as is" information, the form and content of which corresponds to the originally published announcement. The rights to the original texts remain unrestrictedly with the respective publishers or copyright holders. This portal merely assumes a structural categorization and allocation within the framework of a news-journalistic offer. Independent commercial reuse, systematic reproduction or other use of the content by third parties is only permitted within the framework of the statutory provisions or with the consent of the copyright holder.
About GICS Health
GICS Health is part of the GICS Eleven information portfolio, which focuses primarily on information from listed companies in the health sector. The sector classification serves as a guide to navigate quickly and conveniently through the latest industry-specific news. Individual peer group clusters complement the news offering.
About GICS Eleven

GICS Eleven (G11, GICS11) bundles topic-specific content and enables quick access to relevant information thanks to its gate function. The project is largely based on the Global Industry Classification Standard (GICS®), which was developed by MSCI and Standard & Poor's and enables a breakdown into sectors. GICS® consists of 11 sectors, 24 industry branches, 69 industries and 158 sub-industries.

GICS® is a registered trademark of MSCI Inc. and S&P Dow Jones Indices.

Member of 3R/RSQ Network
Digital Content
Network Alliance
Transparency - Reliability - Credibility
Information regarding Product Information
Friday, 12.12.2025, Calendar Week 50, 346th day of the year, 19 days remaining until EoY.